Senescence Profiling And Biomarker Identification In Cell Product Based On Adipose Tissue-Derived Mesenchymal Stromal Cells
Imagine a powerful type of cell found in our fat, called adipose tissue-derived mesenchymal stromal cells, or ASCs. These cells are like tiny repair kits, capable of developing into different cell types and helping our bodies heal and regulate immunity. Because of these amazing properties, they are being used to create advanced medicines for various conditions.
To make enough of these cellular medicines, ASCs are often grown in a lab, a process called “in vitro expansion.” However, growing them for too long can lead to a state called “cellular senescence.” Think of senescent cells as retired cells; they stop dividing and can even release substances that might harm nearby healthy cells, potentially making the cell therapy less effective.
A recent study explored how to ensure these valuable ASCs remain effective. Researchers investigated cryopreserved (frozen) ASCs to see how well they could still multiply after thawing. They found that these cells largely retain their ability to grow. More importantly, the study identified specific “biomarkers” – essentially, molecular signals or changes in gene activity – that reliably indicate when cells are starting to become senescent. These changes were consistent across different cell batches, suggesting they are robust indicators of cell aging in the lab.
This discovery is a big step forward for cell-based therapies. By identifying these biomarkers, scientists can develop better “quality control assays” – tests to check the health and effectiveness of the ASC products. This means we can ensure that the cell therapies given to patients are safe, consistent, and have the best chance of working as intended, ultimately improving the reliability of these innovative treatments.
Source: link to paper